Supplemental figures from CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies

Supplemental Figure 1. Assessment of the binding characteristics and cynomolgus monkey cross-reactivity of CD20-TCB. Supplemental Figure 2. Tumor cell lysis mediated by different CD20-targeting TCB antibodies. Supplemental Figure 3. T-cell and B-cell counts along with E:T ratio upon CD20-TCB treatment of primary bone marrow aspirates from patients with lymphoma and leukemia. Supplemental Figure 4. Quantification of interactions between T-cells and tumor cells from live imaging experiments and kinetic analysis of T-cell activation and exhaustion marker expression. Supplemental Figure 5. Secretion of cytokines, cytotoxic granules and T-cell proliferation upon tumor lysis. Supplemental Figure 6. Assessment of the cytokine-mediated endothelial cell activation. Supplemental Figure 7. Characterization of stem cell humanized mice (HSC-NSG) generated in house.